Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
Last Thursday, April 18th, Mustang Bio (MBIO) exploded for a whopping 84% gain despite closing well off its daily high. This move was in response to news that St. Jude Children's Research Hospital … [Read more...] about Will Mustang Bio Run?
Some of the hottest stocks on the market are in the biotech sector. Of these, some of the hottest of the hot are in the NAFLD/NASH space. The reason being is the magnitude of disease prevalence and … [Read more...] about Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years
Zoom has announced that it will be going public on April 18th 2019. This has generated substantial hype and lead to a valuation of $36 per share tomorrow. In this article I will discuss; Potential … [Read more...] about Should You Buy The ZOOM IPO?
Whats Happening? Novavax Inc. (Nasdaq: NVAX) is getting attention lately as investors debate the potential of the company’s respiratory syncytial virus (RSV) vaccination “ResVax”, a proposed 1:20 … [Read more...] about NVAX At A Glance
You voted and we heard you. After my initial article on a few noteworthy results from AACR 2019, we asked you the subscribers to choose one of the four companies that you would like to learn more … [Read more...] about An In-Depth Assessment Of TG Therapeutics
Background Investors have recently been faced with many headwinds in the first half of 2019. With potential threats to Bulls positions constantly surfacing, 2019 has been volatile to say the least. … [Read more...] about Why I’m Bullish With Brexit
This stock has been at the top of our buy list since February. Despite Adma Biologics (Nasdaq: ADMA) gaining 78% in the past few months the share price still has room for near-term growth. Luckily, … [Read more...] about MS Number 1 Pick For April 2019
In a new series for MS Money Moves Premium Members, Chris Stang a PharmD candidate at the University of Findlay and Nationwide Pharmacy Intern will evaluate a few pieces of data releases from health … [Read more...] about Eye-Catching Results at AACR 2019: A Quick Road Map
At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase